Pregabalin Capsule
Product Images NDC 72162-1546

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1546). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621546)

Label (Lbl721621546)
Each capsule of this drug contains 200mg of Pregabalin, a medication for nerve pain and seizures. It should be kept out of the reach of children and stored between 20-25°C (68°-77°F) with short excursions permitted up to 15-30°C (59°-86°F). The drug is available in 90 capsules per package and has been repackaged by Bryant Ranch Prepack, Inc. It is manufactured by ScieGen Pharmaceuticals, Inc. This drug is available only with a prescription.*
FDA Label Image

Figure 1 (Pregabalin Fig01)

Figure 1 (Pregabalin Fig01)
This is a report that shows a chart depicting the percent of patients that improved their pain, with numbers ranging from 88 to 3. There is also a line graph showing percentage improvement in pain from baseline, although the values are not clear.*
FDA Label Image

Figure 2 (Pregabalin Fig02)

Figure 2 (Pregabalin Fig02)
This text is a table that shows the percentage of patients who improved after taking Pregabalin 160mg for three days. It also includes a chart that presents the percentage improvement in pain from baseline at different time intervals, but the data is not in a readable format.*
FDA Label Image

Figure 3 (Pregabalin Fig03)

Figure 3 (Pregabalin Fig03)
This text appears to be a table displaying different medications (Pregatalin, Pregabain, Pregabalin, and Flaosbo) with their respective dosages and the percentage of patients who improved while taking them. It also shows the percentage improvement in pain compared to a baseline. However, the format of the text and the presence of characters that do not constitute a language make it difficult to obtain more detailed information.*
FDA Label Image

Figure 4 (Pregabalin Fig04)

FDA Label Image

Figure 5 (Pregabalin Fig05)

FDA Label Image

Figure 6 (Pregabalin Fig06)

Figure 6 (Pregabalin Fig06)
This appears to be a table that includes information about several studies, dosages, and statistical significance. Without more context, it is difficult to provide a more detailed description.*
FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

Figure 9 (Pregabalin Fig08)
The text displays a chart presenting the percentage of patients who improved while taking Pregabalin at different doses, compared to placebo. The X-axis shows the percentage of improvement in pain from the baseline, while the Y-axis shows the different doses tested. There is not enough information provided to explain what type of pain or condition was being treated.*
FDA Label Image

Figure 10 (Pregabalin Fig09)

Figure 10 (Pregabalin Fig09)
This section presents a chart showing the estimated percentage of subjects without LTR (Likely Therapeutic Response) for two treatments, Progabain and Placebo, over a period of 180 days. The percentage values range from 0% to 100%. The chart also displays the timeline of the study with days numbered from 0 to 180.*
FDA Label Image

Figure 11 (Pregabalin Fig10)

FDA Label Image

Figure 12 (Pregabalin Fig11)

Figure 12 (Pregabalin Fig11)
The text appears to show a table comparing the percentage of subjects improved using Pregabalin and Placebo. The table includes data points at week 16 and shows improvement percentages at 100, 210, 220, 230, 240, 250, 260, 270, and 280.*
FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Cockcroft And Gault Equation (Pregabalin Formula)
This text appears to be a formula for calculating creatinine clearance (CLCT) based on age, weight, and serum creatinine levels. The formula is given as "[140 - age (years)] x weight (kg) x mmmmmmmmm e e (x 0.85 for female patients) / 72 x serum creatinine (mg/dL)". However, the characters "mmmmmmmmm e e" are not readable and this may affect the accuracy of the formula.*
FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.